BioPharma Resources

Drug Trial Radar · NCT06305247

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours

An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

36

Actual

Start

Apr 3, 2024

Primary completion

Mar 20, 2028

Study completion Mar 20, 2028

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Mar 12, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body. In this study, all participants will receive the study drug, which will be taken by mouth (orally).

Conditions

  • Melanoma
  • Head and Neck Squamous Cell Carcinoma
  • Pancreatic Ductal Adenocarcinoma
  • Colorectal Cancer
  • Solid Tumor

Interventions

  • IPN01194Drug

    IPN01194 will be taken orally over a period of 28 days (a "Cycle") at the assigned dose level. The dose limiting toxicity (DLT) observation period consists of the first 28 days of treatment with IPN01194 (Cycle 1). Participants will receive IPN01194 treatment beyond Cycle 1 until treatment is precluded by toxicity, disease progression, or upon participant's request or investigator decision.

  • IPN01194Drug

    All participants will receive IPN01194 orally for 28-day cycles at one of the two dose levels determined at the end of Phase I. Participants will receive IPN01194 treatment until treatment is precluded by toxicity, disease progression, or upon participant's request or investigator decision

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Percentage of participants with dose limiting toxicity (DLT)Time frame: Within 28 days of first dose
  2. Phase 1: Percentage of participants experiencing Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TE SAEs)Time frame: At 30 days following the last administration of study intervention
  3. Phase 1: Percentage of participants with dose interruptions and permanent treatment discontinuationsTime frame: At 30 days following the last administration of study intervention
  4. Phase 2a: Objective response rate (ORR)Time frame: At end of treatment (up to approximately 32 months)

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • The Angeles Clinic and Research Institute - California

    Los Angeles, California

  • UC San Diego Health System - La Jolla

    San Diego, California

  • Yale Cancer Center - New Heaven

    New Haven, Connecticut

  • Sarah Cannon Research Institute (SCRI) - Nashville

    Nashville, Tennessee

  • Virginia Cancer Specialist

    Fairfax, Virginia

  • Centre Léon Bérard - Lyon

    Lyon, France

  • Paris Saint-Louis

    Paris, France

  • Institut de Cancerologie de l'Ouest (St-Herblain)

    Saint-Herblain, France

  • IGR-Villejuif

    Villejuif, France

  • Barcelona - Val D'Hebron

    Barcelona, Spain

  • Fundacion Jimenez Diaz - Madrid

    Madrid, Spain

  • M.D. Anderson Cancer Center Madrid

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.